Major
Established
Description
Ibuprofen with dabigatran increases GI bleeding risk through additive effects; dabigatran itself carries a higher inherent GI bleeding risk than other DOACs.
Mechanism
NSAIDs impair platelet function and damage gastric mucosa; dabigatran inhibits thrombin, preventing fibrin clot formation at sites of mucosal injury created by ibuprofen.
Clinical Significance
Dabigatran's GI bleeding rate is already higher than warfarin; NSAID co-administration amplifies this risk substantially.
Management
Avoid combination; use acetaminophen for pain. If NSAID is unavoidable, use the lowest dose for the shortest duration with a PPI, and reassess dabigatran dose.